Background
==========

Chronic inflammatory bowel diseases (IBD) such as Crohn\'s disease (CD) and ulcerative colitis (UC) appear to be the result of an unbalanced immune response to luminal antigens. There is evidence from clinical trials and animal experiments that alteration of the composition of the intestinal microflora by antibiotic treatment can induce and maintain remission \[[@B1]\].

Recently, probiotic microorganisms received much scientific attention due to reports of successful treatment of various intestinal, mainly infectious disorders \[[@B2]\]. Furthermore, there are reports on successful induction and maintenance of remission of chronic pouchitis \[[@B3]\] and ulcerative colitis \[[@B4]\], but treatment of Crohn\'s disease with probiotic preparations proved difficult \[[@B5]-[@B7]\]. While *L*. GG and *E. coli*strain Nissle 1917 were ineffective in preventing recurrence after curative resection in CD or maintaining medically induced remission \[[@B5],[@B6]\], the probiotic compound VSL\#3 together with antibiotic therapy was beneficial in prevention of post-operative recurrence of Crohn\'s disease \[[@B8]\], and *L*. GG led to a significant clinical improvement in pediatric CD patients \[[@B7]\], but no clinical trials were performed to test the ability to maintain a medically induced remission in adult CD.

The mechanisms by which probiotic microorganisms mediate their therapeutic effects are not fully understood. Probiotic microorganisms exert their action through a temporary modulation of the intestinal bowel flora \[[@B9],[@B10]\] and by that might influence the intestinal immune system \[[@B11],[@B12]\]. *In vitro*, *lactobacilli*induce the secretion of a variety of cytokines \[[@B13]-[@B16]\], and *in vivo*, these microorganisms appear to shift a Th1-mediated immune response to intestinal bacteria to a Th-2-dominated response \[[@B11],[@B12]\]. Since especially CD appears to be a Th1-driven disease, with an overly aggressive immune response to the intestinal microflora, probiotics should theoretically be able to alter the course of the disease \[[@B17],[@B18]\].

The aim of this study was therefore to evaluate the effect of oral *L*. GG on induction and maintenance of remission in patients with moderate to active CD.

Methods
=======

Patients
--------

A total of 11 patients were with moderate to active Crohn\'s disease ([CDAI 150--300]{.ul}) were enrolled in this randomized, double-blind, placebo-controlled trial. The ethical review panel of the University of Regensburg, School of Medicine approved the study protocol and informed consent was obtained prior to enrollment in the trial. At the beginning of the study, both groups were comparable in demographic characteristics (age, gender), in CDAI (269 ± 44 vs. 304 ± 27), and c-reactive protein (CRP; 32 mg/l ± 11 mg/l vs. 54 mg/l ± 21 mg/l).

Treatment protocol
------------------

The study profile is outlined in Figure [1](#F1){ref-type="fig"}. Following baseline examination to determine eligibility, all patients were started on oral antibiotic treatment (ciprofloxacin 500 mg bd, metronidazole 250 mg tds) to be continued for 2 weeks. Following week 1, the patients were randomized to receive either *L*. GG (n = 5)(2 × 10^9^CFU/day; CAG Functional Foods, Omaha, NE) or placebo (n = 6). The probiotic therapy was continued for 6 months.

![Outline of the study protocol](1471-230X-4-5-1){#F1}

For the first 12 weeks, a standard tapering regime of corticosteroids, beginning with 60 mg p.o. per day was administered. Follow up visits were carried out after 2, 4, 8, 12, 18 weeks and after 6 months.

Statistical analysis
--------------------

The primary end point was reached at 6 months in sustained remission or at time of relapse. Secondary end points were tolerability, possible side effects of the study medication and impact on c-reactive protein. Relapse was defined as an increase in CDAI of \>100 points. Statistical analyses were performed using a test for normality, followed by a t-test or a Mann-Whitney Rank Sum Test. The probability for relapse was calculated using the Kaplan-Meier method (SPSS for windows, Version 11.0).

Due to slow inclusion rates and negative reports of the effect of L. GG in maintenance of remission in CD, the enrolment of patients was stopped prematurely, resulting in a small study population.

Results
=======

Apart from mild bloating, no significant side effects were reported.

A total of 11 patients were enrolled into the trial. 5/11 patients finished the study period, with 2 patients in each group in sustained remission (table [1](#T1){ref-type="table"}). Four patients in the verum group and 5 patients in the placebo group reached remission during the observation period but 2 patients receiving *L*. GG and 3 patients on placebo relapsed.

###### 

Study characteristics

            pts.    CDAI\*     CRP\* in mg/l   remission   sustained remission   Relapse   mean time to relapse (in weeks)
  --------- ------- ---------- --------------- ----------- --------------------- --------- ---------------------------------
  *L*. GG   n = 5   269 ± 44   32 ± 11         4/5         2/4                   2/4       16 ± 4
  Placebo   n = 6   304 ± 27   54 ± 21         5/6         2/5                   3/5       12 ± 4.3\*\*

\*at time of recruitment \*\*ns

In the verum group, 2 patients had signs of a clinical relapse in week 12, and 1 patient still had active disease at the end of the trial. One of the patients with signs of a clinical relapse developed an intestinal abscess, but no *L*. GG could be identified by culture.

In the placebo arm, 2 patients showed signs of a relapse in week 4 and respectively in week 8, while another patient relapsed in week 12. One patient had to be taken out of the trial due to ileocaecal resection in week 8.

The mean time to relapse was 16 ± 4 weeks in the *L*. GG group and 12 ± 4.3 weeks in the placebo group (p = 0.5) (Fig. [2](#F2){ref-type="fig"}). All other parameters (CDAI, CRP) were not altered in both groups.

![Time to relapse as depicted by Kaplan-Meier survival estimates.](1471-230X-4-5-2){#F2}

Discussion
==========

There is mounting evidence from clinical trials and animal studies, demonstrating the beneficial effects of probiotic preparations in the treatment chronic intestinal disorders such as ulcerative colitis and pouchitis. However, in Crohn\'s disease, there are conflicting reports in the literature. *Saccharomyces boulardii*and the probiotic preparation VSL\#3 were promising in clinical trials in the maintenance of medically or surgically induced remission of CD \[[@B19]-[@B21]\], but *E. coli*Nissle 1917 was not beneficial in Crohn\'s disease \[[@B5]\]. Gupta et al. conducted a small open trial using *L*. GG in children with Crohn\'s disease and was able to document clinical improvement \[[@B7]\]. However, in a larger follow-up study, Bousvarous et al. were not able to show an effect of adding *L*. GG to standard maintenance therapy in children with Crohn\'s disease \[[@B21]\]. In a recent trial by Prantera et al. *L*. GG was added to postoperative treatment to maintain remission in Crohn\'s disease with no clinical benefits seen \[[@B6]\].

In our trial, we could not demonstrate a benefit of *L*. GG in inducing remission in CD. While this observation could be due to the short observation period of six months, in 2/5 patients of the *L*. GG group, relapse occurred in week 12, at the end of the tapering steroid medication. This was also seen in the placebo group, where two patients relapsed at week 4 or respectively week 8 and therefore is probably due to the fact of reducing the steroid medication. Only 1/5 patients in the placebo arm went into remission and relapse at the end of the study period. 2/5 patients receiving *L*. GG and 2/6 patients in the placebo group achieved and maintained remission. Due to the small sample size and 1 patient not finishing the trial in the placebo arm, we are not able to comment on the effect of *L*. GG to maintain remission once the steroid medication had ceased.

Conclusions
===========

In this study we could not demonstrate a benefit of *L*. GG in inducing or maintaining medically induced remission in CD.
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